Clinical Outcome of Third-Line Pazopanib in a Patient With Metastatic Renal Cell Carcinoma

Case Reports in Oncological Medicine - Egypt
doi 10.1155/2015/629046
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Hindawi Limited

Related search

Pazopanib-Induced Liver Toxicity in Metastatic Renal Cell Carcinoma (mRCC) Patients: Impact of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety and Patient Outcome

Clinical Genitourinary Cancer
OncologyUrology
2020English

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

Clinical Impact of Targeted Therapies in Patients With Metastatic Clear-Cell Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2014English

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2018English

Efficacy of Vertebral Cryoablation and Immunotherapy in a Patient With Metastatic Renal Cell Carcinoma: A Case Report

Journal of Medical Case Reports
Medicine
2019English

Angiogenesis Genotyping in the Selection of First-Line Treatment With Either Sunitinib or Pazopanib for Advanced Renal Cell Carcinoma

Oncotarget
Oncology
2016English

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2019English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy